

# **Press Release**

Zutphen, The Netherlands, 1 November 2011

# Cryo-Save Group N.V. — strong third quarter results Revenue up 9% to €10.5 million and net profit up 74% to €0.6 million

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international family stem cell bank, announces its trading update for the guarter ended 30 September 2011.

### Financial highlights for the period were:

- Third quarter revenue up 9% to €10.48 million (Q3 2010: €9.61 million). For the period to 30 September 2011, revenue was up 8% to €31.60 million (30 September 2010: €29.14 million)
- EBITA\* up 7% to €1.13 million (Q3 2010: €1.06 million). For the period to 30 September 2011, EBITA was up 9% to €3.86 million (30 September 2010: €3.54 million)
- Operating profit of €0.73 million (Q3 2010: €0.75 million). For the period to 30 September 2011, operating profit was up 3% to €2.70 million (30 September 2010: €2.61 million)
- Net profit up 74% to €0.57 million (Q3 2010: €0.33 million). For the period to 30 September 2011, net profit was up 17% to €1.86 million (30 September 2010: €1.59 million)

## Operational highlights for the period were:

- 10,000 new samples stored in Q3 2011, up 6% (Q3 2010: 9,400). Of these, 6,200 were new cord blood samples and 3,800 new cord tissue samples. For the period to 30 September 2011, 29,600 new samples were stored, up 6% (30 September 2010: 27,900)
- 194,000 samples have now been stored in total
- `FDA-ready' validation study of Cryo-Lip® completed in the US and partnership with Texas-based Genesis Biosystems to market Cryo-Lip® in the US
- State-of-the-art stem cell processing and storage laboratory opened in Cape Town, South Africa
- Accreditation by Swissmedic, the Swiss government agency for therapeutic products, confirming Cryo-Save's delivery of high quality, and safe and effective procedures
- A six-year-old girl from Portugal with Cerebral Palsy was treated at Duke University in the US with her own cord blood stem cells, stored and released by Cryo-Save

<sup>\*</sup> EBITA is defined as Earnings Before Interest, Taxation and Amortization of identified intangible assets

## Highlights after 30 September 2011 were:

- First stem cell bank in India to receive World Health Organisation Good Manufacturing Procedures (WHO-GMP) certification, guaranteeing the superior quality, safety and effectiveness of the service
- Proactive contribution in increasing awareness of stem cell therapies and regenerative medicine amongst healthcare professionals. Examples of these were:
  - Launch of the LIVECORD project with the Italian Association of Hospital Obstetricians and Gynaecologists (AOGOI), dedicated to providing education and accurate information on the cryopreservation of stem cells and their uses in clinical therapeutic treatments to medical and paramedical staff
  - Participation and support of the International Symposium on Clinical Applications of Stem Cell Therapies in Belgrade, Serbia where several key researchers and scientists presented on topics regarding transplantation, cord blood, heart disease and many other modern clinical applications of stem cell therapies
  - Attendance and sponsorship of the umbilical cord blood charity gala in Bern, Switzerland, organized by Professor Surbek, one of the leading gynaecologists in Switzerland

#### **Arnoud van Tulder**, Chief Executive officer, commented:

"We are pleased to report continued revenue growth along with solid returns, allowing us to maintain our investment in the improvement and quality of our services.

"The acceptance of our samples by treating physicians, the accreditation in Switzerland and the certification in India are great endorsements of the quality of our products and service. The enthusiasm of organisations such as Genesis Biosystems in the US and AOGOI in Italy to partner with Cryo-Save demonstrates our market leading position".

#### **Enquiries:**

Cryo-Save Group + 31 (0) 575 548 998

Arnoud van Tulder, Chief Executive Officer

SPJ Financiële Communicatie (The Netherlands) +31 (0)20 647 8181

Kees Jongsma/Leon Melens

Daniel Stewart & Company plc (UK) + 44 (0) 20 7776 6550

Sean Lunn

College Hill (UK) + 44 (0) 20 7457 2020

Rozi Morris/ Adrian Duffield

Free footage is available on www.videobankonline.com.

## About Cryo-Save (<u>www.cryo-save.com/group</u>)

Cryo-Save, the leading international family stem cell bank, already stores more than 194,000 samples from cord blood and umbilical cord tissue for newborns and adipose tissue for adults. These stem cells can mean the difference between life and death in the case of future threats to the health of the donors. There are already several diseases that can be cured by the use of stem cells, and the number of treatments will only increase. The use of stem cells from adipose tissue is increasingly popular in plastic surgery. Driven by its international business strategy, Cryo-Save is now represented in over 40 countries on four continents, with ultra-modern processing and storage facilities in the United States, Belgium, Germany, Dubai, India, South Africa and France (validation in progress).